Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Sotirios G. Papageorgiou, Thomas Thomopoulos, Athanasios Liaskas, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 1917-1917
Open Access | Times Cited: 20

Showing 20 citing articles:

Mechanisms of Cancer Resistance to Various Therapies
Asiya Batool, Waseem Rashid, Kaneez Fatima, et al.
(2024), pp. 31-75
Closed Access | Times Cited: 5
Role of Folate Receptor and CD44 in Targeting of Docetaxel and Paclitaxel Fabricated Conjugates for Efficient Cancer Therapy
Amol Tatode, Pranav Agrawal, Jayshree Taksande, et al.
Journal of Medicine Surgery and Public Health (2024), pp. 100163-100163
Open Access | Times Cited: 4
Research Advances in Primary Intestinal Lymphoma
红丽 熊
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1386-1396
Closed Access
The role of B cells in systemic sclerosis
Takemichi Fukasawa, Asako Yoshizaki‐Ogawa, Shinichi Sato, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 7, pp. 904-913
Closed Access | Times Cited: 3
B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas
Haijun Gu, Jia He, Yuzhan Li, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 23, pp. 15559-15583
Closed Access | Times Cited: 16
Involvement of B cells in the development of systemic sclerosis
Ayumi Yoshizaki, Takemichi Fukasawa, Satoshi Ebata, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma
Khalil Saleh, Rita Khoury, Nadine Khalife, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 666-666
Open Access | Times Cited: 2
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors
Sara Piccinelli, Rizwan Romee, Roman M. Shapiro
Seminars in Hematology (2023) Vol. 60, Iss. 1, pp. 42-51
Closed Access | Times Cited: 5
Development and Validation of a Cell-Based Binding Neutralizing Antibody Assay for an Antibody–Drug Conjugate
Weifeng Xu, Nazneen Bano, Olguitza Guzman-Valdes, et al.
The AAPS Journal (2024) Vol. 26, Iss. 3
Closed Access | Times Cited: 1
Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation
Hong-Kun Sun, Juanjuan Shang, Xiao Liu, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma
Xin Wu, Sun Xiaoying, Woding Deng, et al.
Heliyon (2024) Vol. 10, Iss. 14, pp. e34068-e34068
Open Access | Times Cited: 1
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
Vincent Camus, Roch Houot, Gabriel Brisou, et al.
Blood Advances (2024) Vol. 8, Iss. 20, pp. 5371-5381
Open Access | Times Cited: 1
The Role of Geriatric Assessment in the Management of Diffuse Large B-Cell Lymphoma
Francesco Merli, Stefano Pozzi, Hillary Catellani, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5845-5845
Open Access | Times Cited: 3
T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update
Shalini Balendran, Constantine S. Tam, Matthew Ku
Journal of Clinical Medicine (2023) Vol. 12, Iss. 21, pp. 6737-6737
Open Access | Times Cited: 2
Systems Drug Discovery for Diffuse Large B Cell Lymphoma Based on Pathogenic Molecular Mechanism via Big Data Mining and Deep Learning Method
Shan‐Ju Yeh, Tsun-Yung Yeh, Bor‐Sen Chen
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6732-6732
Open Access | Times Cited: 4
Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital
Yu. E. Ryabukhina, P. A. Zeynalovа, О. Л. Тимофеева, et al.
MD-Onco (2024) Vol. 4, Iss. 2, pp. 55-64
Open Access
The role of antibody-based therapies in treating relapsed chronic lymphocytic leukemia
Magdalena Witkowska, Agata Majchrzak, Paweł Robak, et al.
Expert Opinion on Biological Therapy (2024)
Closed Access
Non-viral, precisely engineered immune cells tested in lymphoma

Nature (2022)
Closed Access
The Toxicity of Escalated Interleukin-2 as Part of the R-CHOP Regimen in Patients with Diffuse Large Β-cell Lymphoma
О.А. Каленик, Н.Е. Конопля
Евразийский онкологический журнал (2022), Iss. 3, pp. 191-200
Open Access
Development of non-viral site-specific integrated CAR-T technology and its application in clinical treatment of relapsed/refractory B-cell non-Hodgkin lymphoma
Yanyan Wei, Shouxiang Jiang
Chinese Science Bulletin (Chinese Version) (2022) Vol. 67, Iss. 34, pp. 4036-4038
Closed Access
Page 1

Scroll to top